Date: 3/15/14 NCCN Guidelines® Insights: Non-Hodgkin’s Lymphomas, Version 1.2013 Expiration Date: 3/15/14 Optimizing Neoadjuvant Therapy for Rectal Cancer With Oxaliplatin Expiration Date: 3/15/14 CASE REPORT: A Patient With Anaplastic
Search Results
fluorouracil IV continuously over 46 hours on days 1 and 15, OR oxaliplatin IV over 2 hours, leucovorin calcium IV over 2 hours, and fluorouracil IV continuously over 46 hours on days 1 and 15. Treatment repeats every 28 days for up to 4 courses in the absence
Manish A. Shah and David P. Kelsen
prolonged higher quality of life than those undergoing best supportive care ( P < .05). 36 Notably, none of these trials used cisplatin or other current chemotherapy agents known to have activity in gastric cancer (e.g., docetaxel, irinotecan, oxaliplatin
Christopher M. Booth, Sulaiman Nanji, Xuejiao Wei, Yingwei Peng, James J. Biagi, Timothy P. Hanna, Monika K. Krzyzanowska, and William J. Mackillop
oxaliplatin to 5-FU (FOLFOX). 3 Another landmark RCT in 2005 showed that oral capecitabine chemotherapy could be substituted for 5-FU. 4 Accordingly, standard of care for patients with stage III colon cancer includes ACT with 5-FU/capecitabine with or
Jaffer A. Ajani, Thomas A. D’Amico, David J. Bentrem, Joseph Chao, Carlos Corvera, Prajnan Das, Crystal S. Denlinger, Peter C. Enzinger, Paul Fanta, Farhood Farjah, Hans Gerdes, Michael Gibson, Robert E. Glasgow, James A. Hayman, Steven Hochwald, Wayne L. Hofstetter, David H. Ilson, Dawn Jaroszewski, Kimberly L. Johung, Rajesh N. Keswani, Lawrence R. Kleinberg, Stephen Leong, Quan P. Ly, Kristina A. Matkowskyj, Michael McNamara, Mary F. Mulcahy, Ravi K. Paluri, Haeseong Park, Kyle A. Perry, Jose Pimiento, George A. Poultsides, Robert Roses, Vivian E. Strong, Georgia Wiesner, Christopher G. Willett, Cameron D. Wright, Nicole R. McMillian, and Lenora A. Pluchino
/leucovorin calcium/oxaliplatin) as a category 1 preferred option for preoperative chemoradiation. The efficacy and safety of preoperative FOLFOX combined with radiation therapy (RT) was evaluated in a single-arm phase II SWOG trial involving 93 patients with
Kohei Shitara and Atsushi Ohtsu
(LV) versus S-1 plus LV and oxaliplatin (SOL) versus S-1 plus cisplatin in patients with AGC showed a higher response rate to SOL with a longer OS ( Table 1 ). 16 Currently, a phase III SOLAR study comparing TAS-118 (S-1 and LV) plus oxaliplatin with
Ronan J. Kelly
NCCN regimens: the CROSS regimen of neoadjuvant CRT before esophagectomy or perioperative chemotherapy with either FOLFOX (5-fluorouracil/leucovorin/and oxaliplatin) or FLOT (5-FU/leucovorin/oxaliplatin/docetaxel; for esophageal carcinoma only
Al B. Benson III, Alan P. Venook, Tanios Bekaii-Saab, Emily Chan, Yi-Jen Chen, Harry S. Cooper, Paul F. Engstrom, Peter C. Enzinger, Moon J. Fenton, Charles S. Fuchs, Jean L. Grem, Axel Grothey, Howard S. Hochster, Steven Hunt, Ahmed Kamel, Natalie Kirilcuk, Lucille A. Leong, Edward Lin, Wells A. Messersmith, Mary F. Mulcahy, James D. Murphy, Steven Nurkin, Eric Rohren, David P. Ryan, Leonard Saltz, Sunil Sharma, David Shibata, John M. Skibber, Constantinos T. Sofocleous, Elena M. Stoffel, Eden Stotsky-Himelfarb, Christopher G. Willett, Kristina M. Gregory, and Deborah Freedman-Cass
improvement in 3-year DFS when oxaliplatin was added to 5-FU in both neoadjuvant and adjuvant treatment (75.9% vs 71.2%; P =.03). 22 Based on these results, the panel agreed that CapeOx and FOLFOX should be preferred over 5-FU/LV or capecitabine in the
Jaffer A. Ajani, Thomas A. D’Amico, David J. Bentrem, Joseph Chao, David Cooke, Carlos Corvera, Prajnan Das, Peter C. Enzinger, Thomas Enzler, Paul Fanta, Farhood Farjah, Hans Gerdes, Michael K. Gibson, Steven Hochwald, Wayne L. Hofstetter, David H. Ilson, Rajesh N. Keswani, Sunnie Kim, Lawrence R. Kleinberg, Samuel J. Klempner, Jill Lacy, Quan P. Ly, Kristina A. Matkowskyj, Michael McNamara, Mary F. Mulcahy, Darryl Outlaw, Haeseong Park, Kyle A. Perry, Jose Pimiento, George A. Poultsides, Scott Reznik, Robert E. Roses, Vivian E. Strong, Stacey Su, Hanlin L. Wang, Georgia Wiesner, Christopher G. Willett, Danny Yakoub, Harry Yoon, Nicole McMillian, and Lenora A. Pluchino
regimen should be reserved for medically fit patients with excellent PS and easy access to frequent toxicity evaluations (see GAST-F 1 of 16, page 176). 78 Oxaliplatin is generally preferred over cisplatin due to lower toxicity. Trastuzumab should be
Al B. Benson III, Tanios Bekaii-Saab, Emily Chan, Yi-Jen Chen, Michael A. Choti, Harry S. Cooper, Paul F. Engstrom, Peter C. Enzinger, Marwan G. Fakih, Charles S. Fuchs, Jean L. Grem, Steven Hunt, Lucille A. Leong, Edward Lin, Michael G. Martin, Kilian Salerno May, Mary F. Mulcahy, Kate Murphy, Eric Rohren, David P. Ryan, Leonard Saltz, Sunil Sharma, David Shibata, John M. Skibber, William Small Jr, Constantinos T. Sofocleous, Alan P. Venook, Christopher G. Willett, Deborah A. Freedman-Cass, and Kristina M. Gregory
trial compared the preoperative use of infusional 5-FU with or without oxaliplatin versus capecitabine with or without oxaliplatin in 1608 patients with stage II or III rectal cancer. 129 No differences in complete pathologic response, sphincter
